BMY vs PFE
BMY: A diversified biopharmaceutical company leveraging immunotherapy, cell therapies, and small-molecule platforms to address cancer, autoimmune disease, and specialty care. PFE: Global biopharmaceutical company discovering, developing, and manufacturing prescription medicines and vaccines across oncology, immunology, cardiovascular, and infectious disease.
Side-by-side fundamentals
| Metric | BMY | PFE | Edge |
|---|---|---|---|
| Price as of 2026-07-09 close | $57.94 | $24.25 | |
| Market cap as of 2026-07-10 | $117.7B | $138.1B | |
| P/E as of 2026-07-10 | 19.69 | 18.44 | PFE lower |
| PEG as of 2026-07-10 | -4.29 | -3.38 | BMY lower |
| Net margin as of 2026-07-10 | +12.3% | +11.8% | BMY higher |
| Gross margin as of 2026-07-10 | +53.7% | +74.8% | PFE higher |
| Operating margin as of 2026-07-10 | +17.1% | +15.4% | BMY higher |
| ROE as of 2026-07-10 | +41.6% | +8.4% | BMY higher |
| ROA as of 2026-07-10 | +8.7% | +3.6% | BMY higher |
| Debt / equity as of 2026-07-10 | 2.22 | 0.72 | PFE lower |
| Revenue growth (YoY) as of 2026-07-10 | +1.8% | +1.4% | BMY higher |
| Revenue CAGR (3y) SEC XBRL | +1.4% | -14.8% | BMY higher |
| Dividend yield as of 2026-07-10 | +4.4% | +7.1% | PFE higher |
| Dividend streak (yrs) SEC XBRL | 5 | 5 | Tie |
| Beta as of 2026-07-10 | 0.24 | 0.29 | |
| 1-year return as of 2026-07-09 close | +22.3% | -5.1% | BMY higher |
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.